Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enhanced passive safety surveillance of the three seasonal influenza vaccines (Influenza vaccination with Intradermal Trivalent Inactivated Influenza vaccine, Trivalent Inactivated Influenza vaccine or Quadrivalent Inactivated Influenza vaccine) during 2017/18 in Europe

Trial Profile

Enhanced passive safety surveillance of the three seasonal influenza vaccines (Influenza vaccination with Intradermal Trivalent Inactivated Influenza vaccine, Trivalent Inactivated Influenza vaccine or Quadrivalent Inactivated Influenza vaccine) during 2017/18 in Europe

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Sep 2018

At a glance

  • Drugs Influenza A virus vaccine (Primary) ; Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Sep 2018 New trial record
    • 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top